Baudax Bio, Inc.
NASDAQ: BXRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Geraldine A. Henwood
- Employees
- 9
- Headquarters
- Malvern, United States
- IPO year
- 2019
- Website
- https://www.baudaxbio.com
Loading BXRX…
Loading profile data…Frequently asked questions about BXRX
What does Baudax Bio, Inc. (BXRX) do?
Baudax Bio, Inc. is a pharmaceutical enterprise dedicated to creating and marketing therapeutic solutions for inpatient and urgent care environments. Their flagship commercial offering is ANJESO, an injectable meloxicam formulation designed to alleviate moderate to severe pain, which can be administered independently or in conjunction with non-N...
Where does BXRX trade?
Baudax Bio, Inc. (BXRX) trades on the NASDAQ Capital Market.
What sector is BXRX in?
Baudax Bio, Inc. (BXRX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Baudax Bio, Inc.?
Geraldine A. Henwood is the chief executive officer of Baudax Bio, Inc. (BXRX).
Where is Baudax Bio, Inc. headquartered?
Baudax Bio, Inc. is headquartered in United States.
Does BXRX pay a dividend?
Baudax Bio, Inc. (BXRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BXRX go public?
Baudax Bio, Inc. (BXRX) completed its initial public offering in 2019.